高级检索
当前位置: 首页 > 详情页

Development and validation of a predictive model for recurrence in postoperative patients with stage ⅠA1-ⅢA non-small cell lung cancer

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Pulmonary and Critical Care Medicine, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Institute of Respiratory Health, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [4]The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital, Chengdu, Sichuan, China. [5]State Key Laboratory of Respiratory Health and Multimorbidity, School of Basic Medicine, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
出处:

关键词: non-small cell lung cancer predictive model recurrence postoperative nomogram

摘要:
Patients of non-small cell lung cancer (NSCLC) face a high risk of recurrence postoperatively, yet there is a lack of comprehensive predictive models that integrate genetic and other multifaceted information.This retrospective cohort study analyzed 911 patients with stage ⅠA1-ⅢA NSCLC in West China Hospital between November 2013 and August 2020, aimed to develop a prediction model incorporating demographic, clinical, pathological, radiological, and genetic data to enhance postoperative risk stratification and inform personalized follow-up and treatment strategies. After Lasso regression and multivariate Cox proportional hazards regression, mutations in JAK1 and STK11, disease stage, visceral pleural invasion (VPI), lymphovascular invasion (LVI), tumor spread through air spaces (STAS), radiological density, cavitary sign, and smoking index (SI), were identified as significant risk factors.These variables were integrated into a nomogram model to classify patients into three risk categories for recurrence: low (total score ≤ 100), moderate (100 < total score ≤ 175.16), and high (total score > 175.16). The performance of the nomogram was rigorously assessed through calibration curves, and decision curve analysis (DCA) and receiver operating characteristic (ROC) curve analysis both in training set [AUC:0.88, 95% CI: 0.83-0.93 1year; AUC: 0.85, 95% CI: 0.81-0.89r 3year, AUC: 0.85, 95% CI: 0.81-0.895year] and validation set (AUC: 0.85, 95% CI: 0.79-0.92 1year; AUC: 0.83, 95% CI: 0.76-0.89 3year, AUC: 0.84, 95% CI: 0.78-0.91 5year).Our multi-source imaging-genomic-clinical model accurately predicts the risk of recurrence after surgery in stage ⅠA1-ⅢA NSCLC patients and can be used for risk stratification to guide clinical follow-up management and postoperative treatment strategies.© 2025. The Author(s).

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
第一作者:
第一作者机构: [1]Department of Pulmonary and Critical Care Medicine, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Pulmonary and Critical Care Medicine, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Institute of Respiratory Health, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [4]The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital, Chengdu, Sichuan, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:65780 今日访问量:0 总访问量:5151 更新日期:2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号